Home Metabolism Casein Kinase

Casein Kinase

Other Metabolism Related Inhibitors

Dehydrogenase Transferase DPP Aminopeptidase Procollagen C Proteinase P450 (e.g. CYP17) Phospholipase (e.g. PLA) Factor Xa PDE DHFR

Isoform-selective Products

Cat.No. Product Name Information Product Use Citations Product Validations
S7085 IWP-2 IWP-2 is an inhibitor of Wnt processing and secretion with IC50 of 27 nM in a cell-free assay, selective blockage of Porcn-mediated Wnt palmitoylation, does not affect Wnt/β-catenin in general and displays no effect against Wnt-stimulated cellular responses. IWP-2 specifically inhibits CK1δ.
Sci Bull (Beijing), 2025, S2095-9273(25)00472-4
Nat Commun, 2025, 16(1):1999
Nat Commun, 2025, 16(1):4688
Verified customer review of IWP-2
S1105 LY294002 LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. This compound also inhibits CK2 with IC50 of 98 nM. It is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
Gut, 2025, gutjnl-2025-335163
Cell Mol Immunol, 2025, 22(5):541-556
Nat Commun, 2025, 16(1):1661
Verified customer review of LY294002
S2248 Silmitasertib (CX-4945) Silmitasertib (CX-4945) is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM in a cell-free assay, although it is less potent against Flt3, Pim1 and CDK1 (inactive in cell-based assay). This compound induces autophagy and promotes apoptosis. Phase 1/2.
Nat Cell Biol, 2025, 27(8):1272-1287
Nat Commun, 2025, 16(1):997
Metabolism, 2025, 162:156060
Verified customer review of Silmitasertib (CX-4945)
S0707 Silmitasertib (CX-4945) sodium salt Silmitasertib (CX-4945) sodium salt is a potent, orally bioavailable and selective inhibitor of casein kinase 2 (CK2) with IC50 of 1 nM against CK2α and CK2α'.
Diabetologia, 2024, 10.1007/s00125-024-06128-1
J Diabetes Investig, 2024, 15(6):684-692
Proc Natl Acad Sci U S A, 2022, 119(12):e2114336119
S7642 D 4476 D 4476 is a potent, selective, and cell-permeant CK1 (casein kinase 1) inhibitor with IC50 of 200 nM and 300 nM in a cell-free assay for CK1 from Schizosaccharomyces pombe and CK1δ, respectively. Also acts as an ALK5 inhibitor with IC50 of 500 nM.
Neoplasia, 2025, 66:101175
Cell Rep Med, 2023, 4(4):101015
Cell Rep, 2023, 42(9):113035
Verified customer review of D 4476
S5265 TBB TBB (4,5,6,7-tetrabromobenzotriazole) is a selective cell-permeable CK2 inhibitor with IC50 values of 0.9 and 1.6 μM for rat liver and human recombinant CK2 respectively.
International Journal of Molecular Sciences, November 26, 2019, 5951
International Journal of Molecular Sciences, November 26, 2019, 5951
Nucleic Acids Research, December 2, 2019, 10977-10993
S8237 IC261 IC261 (SU-5607) is a novel inhibitor of CK1. The IC50 of this compound for CK1 is 16 μM and for Cdk5 is 4.5 mM.
Int J Nanomedicine, 2025, 20:9019-9030
Cell Rep, 2023, 42(7):112812
Cell Metab, 2022, S1550-4131(21)00542-8
S2249 PF 4800567 PF 4800567 is a novel and potent inhibitor of casein kinase 1 epsilon (IC50=32 nM) with greater than 20-fold selectivity over casein kinase 1 delta(IC50=711 nM).
Blood Advances, 2020, 3072-3084
Blood Advances, 2020, 3072-3084
Blood Adv, 2020, 4(13):3072-3084
S6734 PF-670462 PF-670462 is a potent and selective inhibitor of CK1ε and CK1δ with IC50 value of 90 nM and 13 nM, respectively.
NPJ Precis Oncol, 2025, 9(1):274
mSystems, 2025, 10(9):e0043825
J Biomed Sci, 2024, 31(1):72
S9850 (E/Z)-GO289

(E/Z)-GO289 potently and selectively inhibits casein kinase 2 (CK2) at an IC50 of 7 nM in vitro kinase assay.
Autophagy, 2024, 994-1014
Autophagy, 2023, 10.1080/15548627.2023.2281128